US · guidance
NCD 150.7
Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents
Indications and Limitations of Coverage
The medical effectiveness of the above therapies has not been verified by scientifically controlled studies. Accordingly, reimbursement for these modalities should be denied on the ground that they are not reasonable and necessary as required by §1862(a)(1) of the Act.
Revision History
9/27/1999 - Issued decision memo maintaining national noncoverage policy.
History
Version 1
Provenance
- Source
- cms.gov
- Retrieved
- 2026-08-26
- Edition
- mcd-2026-08-26
- Content hash
294101be70a07133c3f604cf2d7b2b89ef59c7cb50702f66ab2b94abe6553038
The link goes to the issuing authority’s own document — the one we read to produce this record. Where a source publishes whole titles rather than sections, your browser may need a moment to jump to the provision.
Unofficial copy of government-published law, reproduced from official sources with full provenance. Not an official publication; verify against official sources before relying on it in a filing. Records in the 'guidance' corpus, and only that corpus, are sub-regulatory (interpretive guidelines, survey procedures) and are not binding law. Validity bounds follow each jurisdiction's declared temporalBasis.